diabetes close up
Subscribe to Diabetes Close Up (DCU). With a year's subscription, you'll receive:
- In-depth coverage of diabetes industry news and research trends
- Alerts on breaking news or important research
- Real time updates on conference proceedings
- Full access to our extensive archives
A LOOK INSIDE THE LATEST ISSUE OF DCU
Outstanding, ADA 2009 is almost upon us! We are privileged to bring you an interview this issue with Dr. Harold Lebovitz who is again the program chair, an extremely high-profile position, for this year's ADA. Dr. Lebovitz is professor of medicine in the division of endocrinology and metabolism at the SUNY Brooklyn. He has served on numerous review committees for the ADA, the NIH, and the VA, and serves on the editorial boards of Diabetes, Obesity and Metabolism, and Diabetes Care. In short, he's a powerhouse who is really generous to share his time and insights with us - we're supremely grateful, as you might imagine, to Dr. Lebovitz, who also has made time to sit on diaTribe's advisory board (our patient newsletter).
The ADA has long been the most exciting, data-rich, and agenda-setting event in the world of diabetes, and this year is no exception... On the drug data front, anticipation abounds. Look out for safety/tolerability/PK/PD data on Eli Lilly's once weekly GLP-1 analog, as well as data from Amylin (Byetta/EOW), XOMA (XOMA 052; anti IL-1 beta antibody), Intekrin (INT-131; selective PPAR gamma modulator), and a slew of other compounds. On the device side, 12-month data from the JDRF CGM study will be discussed, as well as a big set of CGM, pump, and closed-loop studies.
Last year statisticians and researchers scrambled to ensure that data from three large studies - ACCORD, ADVANCE, and the VADT - would be compiled and presented at the conference. The results of the studies left many scratching their heads, and the merits of intensive glucose control in established type 2 diabetes remains an issue of controversy a full year later. The studies will continue to be featured prominently at this year's meeting, and we are eager to see how the story about intensive glucose control has evolved.
If you'd like to read more, then Subscribe to Diabetes Close Up.
IN-DEPTH INTERVIEWS WITH DIABETES AND OBESITY INSIDERS
Dr. Rury Holman is currently Professor of Diabetic Medicine at the University of Oxford. In the past he has served as Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM); Director of the Diabetes Trials Unit; and an Honorary Consultant Physician to the Oxford Radcliffe Hospitals NHS Trust. Read More
Dr. Michael Jaff is the Director of the Vascular Center at Massachusetts General Hospital in Boston, MA, which is a large collaborative program encompassing over 100 doctors who diagnose and treat patients with different forms of peripheral vascular disease (PVD). Read More
In June, Dr. Anne Peters received what many would term the most prestigious award for a clinical endocrinologist – the ADA Outstanding Physician Clinical Award. Read More
After the opening of the J&J Diabetes Institute in Beijing during the Olympic Games in July, we had the chance to sit down with Dr. Ken Moritsugu, Vice President of Global Strategic Affairs at J&J's Diabetes Franchise. Read More
Janis Roszler, author of the "Dear Janis" column in Diabetes Positive!, discusses her desire to bring more worldwide awareness and education about diabetes to people through mass media formats. Read More
DCU co-hosts with biotech expert Mike King a real-time discussion on ACCORD with noted endocrinologists Dr. Jay Skyler and Dr. Irl Hirsch. Read More
DCU talks to noted cardiologist Dr. Steven Nissen about Avandia. Read More
DCU talks to John Eng, who discovered Exenatide (exendin-4). Read More
DCU talks to Children With Diabetes founder Jeff Hitchcock about what industry does well and what it needs to do better. Read More
DCU talks to obesity expert Dr. Xavier Pi-Sunyer about clincial trials, prospects for new therapies, and his view of the "state of the state." Read More
DCU talks to Dr. Irl B. Hirsch about his thoughts on continuous glucose monitoring and glycemic variability, incretins, inhaled insulin, and how diabetes care in America is in a relative state of crisis. Read More
DCU talks to Dr. Zach Bloomgarden about the latest controversy with Galvus, the importance of rimonabant, the potential of continuous glucose monitoring, and much more. Read More
Read our new white paper - "Treating the Diabetes Infrastructure"
welcome!
New to Close Concerns?
Subscribe
Already registered?
Log in
WHAT WE DO
consulting
strategic advice and comprehensive information for those interested in the diabetes industry
diabetes close up
our monthly newsletter
industry reports
periodically we take the long view on trends or on specific breakthroughs.
TEAM
web log
Click here to view the entire Close Concerns weblog
Diabetes Roundup III
Close Concerns is pleased to announce Diabetes Roundup III, a unique 200-page compilation of cogent observations on the diabetes and obesity industries facing the industry today - a followup to our Diabetes Round Up I, published in 2004, and Diabetes Round Up II, published in 2006. Diabetes Round Up III features:
- Detailed financial models for the $20 billion diabetes drug market, the $8 billion blood glucose monitoring market, and $1-plus billion insulin pump market
- An-depth drug pipeline database of 100-plus companies developing over 350 diabetes and obesity therapies (up from 50-plus companies developing over 200 therapies in 2006!)
- Top highlights of the top 10 academic diabetes conferences over the last two years (ADA, ADA Postgraduate Sessions, AADE, AACE, EASD, IDF, the Obesity Society, and others)
- Additional on fifty additional conferences of note (Canadian Diabetes Association; 2nd International Conference on Pre-Diabetes and the Metabolic Syndrome; AIDPIT: Artificial Insulin Delivery Systems, Pancreas, and Islet Transplantation, among others)
- Our selection of the top 25 diabetes-related articles in medical journals over the last year (JAMA, NEJM, Diabetes Care, The Lancet) and detailed reviews of each
- Our reports on over a dozen major analyst meetings over the last year (Amylin, BMS, Eli Lilly, Medtronic, Merck, Novo Nordisk, Orexigen, OSI Pharmaceuticals, Roche, Pfizer, Sanofi, Vivus)
- A detailed calendar of over 30 important upcoming diabetes meetings in 2009 and over a dozen (and growing) in 2010
- The Close Concerns High Five Awards: our assessment of five top diabetes product introductions over the past two years
- Every order comes with a ZIP drive of full detailed notes on each of the 50 conferences (over 2,000 pages in all)
Read the full, highly-praised introduction for our last edition of Diabetes Round Up II here